Global Interleukin-2 Inhibitor Pipeline Landscape 2025

DelveInsight’s 2025 report on the Interleukin-2 (IL-2) Inhibitor Pipeline delivers extensive information on over 8 companies and more than 10 drugs in development. It features profiles of pipeline medications across clinical and non-clinical phases, along with assessments based on product category, development stage, delivery method, and molecular structure. The report also addresses inactive projects in this field.

Obtain a comprehensive summary of Interleukin-2 Inhibitor clinical trial progress and regulatory updates via the detailed overview at https://www.delveinsight.com/sample-request/interleukin-2-il-2-inhibitor-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Key Highlights from the Interleukin-2 Pipeline Report

• On October 8, 2025, M.D. Anderson Cancer Center unveiled a research initiative aimed at assessing whether combining dendritic cells with high-dose IL-2 (Cohort A) leads to longer-lasting infused T cells compared to T cells with high-dose IL-2 alone.

• DelveInsight’s Interleukin-2 pipeline analysis shows a vibrant sector with over 8 active organizations advancing more than 10 therapies for Interleukin-2 management.

• Prominent Interleukin-2 companies include Sanofi, Medicenna Therapeutics, Bioniz Therapeutics, Celerion, Asher Biotherapeutics, Xilio Therapeutics, Aulos Bioscience, Krystal Biotech, Werewolf Therapeutics, Xencor, Shanghai Junshi Biosciences, Egle Therapeutics, and ILTOO Pharma.

• Notable Interleukin-2 pipeline treatments encompass ALT-801, Gemcitabine, Cisplatin, Ipilimumab, Feladilimab, Docetaxel, Rozibafusp Alfa, and more.

Learn about the shifting landscape of Interleukin-2 therapies. Dive into DelveInsight’s thorough Interleukin-2 Pipeline Analysis to examine innovative advancements at Interleukin-2 Clinical Trials and Studies

Profiles of Emerging Interleukin-2 Drugs

• Aldesleukin: ILTOO Pharma
  Aldesleukin interacts with the IL-2 receptor, promoting dimerization of the cytoplasmic segments of the IL-2R beta and gamma chains, activating the tyrosine kinase Jak3, and leading to phosphorylation of tyrosine sites on the IL-2R beta chain. This forms an active receptor complex that attracts signaling molecules, which are then modified by regulatory enzymes linked to the receptor. These processes boost T-cell growth and differentiation. It is used for renal cell carcinoma treatment, enhancing lymphocyte proliferation, stimulating long-term growth of IL-2-dependent cell lines, increasing lymphocyte cytotoxicity, activating killer cells (LAK and NK), and promoting interferon-gamma release. The therapy is currently in Phase II clinical trials.

• XmAb564: Xencor
  XmAb564 is a proprietary monovalent IL-2-Fc fusion protein designed to selectively stimulate and expand regulatory T cells (Tregs) for autoimmune disease treatment. It features reduced affinity for the IL-2 beta receptor (IL-2Rß, CD122) and enhanced affinity for the alpha receptor (IL-2Ra, CD25). Xencor is running a randomized, double-blind, placebo-controlled, dose-escalating Phase 1b trial to assess XmAb564's safety and tolerability via subcutaneous administration in patients with atopic dermatitis and psoriasis. The drug is in Phase I development.

Interleukin-2 Pipeline Report Insights

• The report offers in-depth details on organizations creating therapies for Interleukin-2, including the total number of treatments each is pursuing.

• It categorizes various therapeutic options into early, mid, and late development stages for Interleukin-2 care.

• Interleukin-2 companies focus on targeted drug creation, with details on active and inactive (dormant or terminated) initiatives.

• Interleukin-2 drugs in progress are analyzed by development phase, administration route, target receptor, standalone or combined use, mechanism of action, and molecular category.

• Comprehensive review of partnerships (including company-to-company and company-academia collaborations), licensing arrangements, and funding strategies to propel the Interleukin-2 market forward.

Explore innovative treatments and trials in the Interleukin-2 Pipeline. Get DelveInsight’s full report today at New Interleukin-2 Drugs

Interleukin-2 Companies

Key players include Sanofi, Medicenna Therapeutics, Bioniz Therapeutics, Celerion, Asher Biotherapeutics, Xilio Therapeutics, Aulos Bioscience, Krystal Biotech, Werewolf Therapeutics, Xencor, Shanghai Junshi Biosciences, Egle Therapeutics, and ILTOO Pharma.

Interleukin-2 Therapeutic Assessment by Route of Administration

The report evaluates pipeline drugs based on delivery methods, grouped into categories such as:

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Interleukin-2 Products by Molecule Type

Products are classified by molecular forms, including:

• Oligonucleotide

• Peptide

• Small molecule

Access DelveInsight’s updated report for strategic insights on future therapies and key advancements at Interleukin-2 Market Drivers and Barriers, and Future Perspectives

Scope of the Interleukin-2 Pipeline Report

• Coverage: Worldwide.

• Interleukin-2 Companies: Sanofi, Medicenna Therapeutics, Bioniz Therapeutics, Celerion, Asher Biotherapeutics, Xilio Therapeutics, Aulos Bioscience, Krystal Biotech, Werewolf Therapeutics, Xencor, Shanghai Junshi Biosciences, Egle Therapeutics, ILTOO Pharma.

• Interleukin-2 Therapies: ALT-801, Gemcitabine, Cisplatin, Ipilimumab, Feladilimab, Docetaxel, Rozibafusp Alfa, and others.

• Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy, or Both.

• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Which organizations are at the forefront of Interleukin-2 drug innovation? Discover in DelveInsight’s specialized Interleukin-2 Pipeline Report—available now at Interleukin-2 Emerging Drugs and Major Companies

Table of Contents

1. Introduction

2. Executive Summary

3. Interleukin-2 (IL-2) Inhibitor: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Interleukin-2 (IL-2) Inhibitor - DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

   • Drug Name: Company Name

   • (Detailed profiles in the full report...)

8. Mid Stage Products (Phase II)

   • Aldesleukin: ILTOO Pharma

   • (Detailed profiles in the full report...)

9. Early Stage Products (Phase I)

   • THOR-707: Sanofi

10. Mid Stage Products (Phase II)

11. Preclinical Stage Products

    • EGL-001: Egle Therapeutics

    • (Detailed profiles in the full report...)

12. Inactive Products

13. Interleukin-2 (IL-2) Inhibitor - Collaborations Assessment- Licensing / Partnering / Funding

14. Interleukin-2 (IL-2) Inhibitor - Unmet Needs

15. Interleukin-2 (IL-2) Inhibitor - Market Drivers and Barriers

16. Appendix

About DelveInsight

DelveInsight is a premier market research and consulting firm dedicated to healthcare, equipping clients with top-tier intelligence and analysis for strategic choices. Our seasoned team of industry specialists, with deep expertise in life sciences and healthcare, delivers bespoke solutions and global insights. Contact us for precise, current data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com